ImmunityBio, the Culver City-based biotech firm focused on innate and adaptive immune activation, has received regulatory approval in the Macau Special Administrative Region of China for nogapendekin alfa inbakicept, marketed as ANKTIVA, in combination with Bacillus Calmette-Guerin for adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The authorisation, granted by Macau’s Pharmaceutical Administration Bureau, was processed via a reliance-based pathway referencing prior decisions by the U.S. Food and Drug Administration and the European Medicines Agency. It represents the first regulatory clearance for the therapy anywhere in Asia and extends ImmunityBio’s footprint to 34 countries and territories worldwide.

Why a reliance pathway matters more than the jurisdiction’s size

The Macau approval is not, in commercial terms, a transformational market entry. Macau’s population is under 700,000 and its healthcare infrastructure, while sophisticated relative to its size, does not represent a large addressable bladder cancer patient pool. What the authorisation does demonstrate is the transferability of ImmunityBio’s existing regulatory dossier across jurisdictions that operate reliance-based review frameworks. By anchoring to the FDA’s April 2024 approval and the European Medicines Agency’s subsequent conditional marketing authorisation, ImmunityBio avoided the cost and timeline of a de novo submission while establishing a legal footing in Asia. For a company of ImmunityBio’s scale, this is a meaningful proof of concept.

Reliance-based pathways have gained traction across the Asia-Pacific region, with several national medicines agencies formalising frameworks that allow applications referencing decisions from stringent regulatory authorities such as the FDA, EMA, Health Canada, and the Therapeutic Goods Administration. Industry observers note that smaller jurisdictions within the region have progressively adopted these mechanisms to accelerate patient access without duplicating resource-intensive reviews. ImmunityBio’s strategy of targeting these pathways in sequence, before pursuing the more demanding regulatory environments of Japan, South Korea, and mainland China, reflects a layered market-entry logic that is now common among mid-sized oncology developers seeking Asian exposure.

What the clinical data behind ANKTIVA actually shows

The evidential base for the Macau approval rests on the QUILT-3.032 registrational trial, a phase 2/3 open-label, single-arm, multicenter study that enrolled patients with BCG-unresponsive NMIBC. The primary cohort, patients with carcinoma in situ, achieved a complete response rate of 71 percent in 82 evaluable patients, with a median duration of response of 26.6 months. Published in NEJM Evidence in late 2022, these results compared favourably against the only other approved agent in this setting at the time: pembrolizumab, which produced a complete response rate of approximately 41 percent with a median duration of 16.2 months in the KEYNOTE-057 trial. ANKTIVA’s superiority on both headline metrics was a central argument in its approval case, though the absence of a head-to-head randomised comparison limits the strength of that assertion.

The durability signal warrants attention. Updated data from the same study, presented at the American Urological Association’s annual meeting and subsequently published, reported that some responders in cohort A remained disease-free beyond 53 months. The longer-term data from cohort B, covering patients with papillary-only disease, showed 96 percent disease-specific survival and 83 percent progression-free survival at 36 months, with cystectomy-free survival exceeding 80 percent at that timepoint. Clinicians tracking the field have noted that bladder-sparing outcomes at three years are particularly significant given that the standard surgical alternative, radical cystectomy, carries substantial morbidity and permanent urinary diversion consequences for most patients. The question observers continue to raise is whether single-arm trial data, without a contemporaneous comparator arm, can reliably establish the true magnitude of benefit in a disease where response definitions, surveillance protocols, and cystectomy thresholds vary across institutions.

How ANKTIVA’s IL-15 mechanism compares with existing immunotherapy options

ANKTIVA operates through a distinct mechanism from the checkpoint inhibitor class that previously dominated BCG-unresponsive NMIBC discussions. As a first-in-class interleukin-15 receptor agonist, the molecule is designed to drive the proliferation and activation of natural killer cells and CD8-positive T cells while avoiding stimulation of regulatory T cells, which can suppress the anti-tumour immune response. This mechanistic profile theoretically addresses one of the core immune deficits in BCG-unresponsive disease: the progressive exhaustion and inadequate recruitment of cytotoxic lymphocytes that allows tumour escape after initial BCG exposure. The combination with BCG leverages the established toll-like receptor-mediated innate immune activation that underpins BCG’s mechanism, while ANKTIVA amplifies and sustains the downstream lymphocyte response.

Whether this translates into meaningful clinical differentiation from alternative salvage strategies, including intravesical gemcitabine and docetaxel combinations or systemic checkpoint inhibition, remains a live question in the urology community. The NCCN has recently updated its bladder cancer guidelines to include the ANKTIVA plus BCG combination for BCG-unresponsive papillary-only disease, a category 2A recommendation reflecting consensus without the backing of a randomised trial. That guideline update preceded the FDA’s own decision on the supplemental biologics licence application for the papillary indication, which ImmunityBio resubmitted in early March 2026 after a prior complete response letter. Regulatory watchers suggest the FDA’s willingness to engage on a resubmission pathway signals residual confidence in the data package, even if the agency previously sought additional manufacturing inspection clearance rather than raising efficacy or safety objections.

What the Asia-Pacific expansion strategy reveals about ImmunityBio’s commercial priorities

ImmunityBio’s international regulatory campaign has followed a recognisable sequence. The company secured FDA approval in April 2024, achieved UK authorisation, obtained conditional marketing approval in the European Union, gained clearance in Saudi Arabia, and has now established its first Asian foothold in Macau. The 34-country and territory target reflects a broad ambition, but commercial execution in each market involves logistics that extend well beyond regulatory authorisation. Reimbursement pathways, hospital formulary listing, BCG supply reliability, and specialist urology infrastructure all determine whether an approved therapy reaches patients in meaningful numbers.

In the Asia-Pacific context specifically, the more consequential regulatory environments remain outstanding. Japan operates through the Pharmaceuticals and Medical Devices Agency, which typically requires additional clinical data or bridging studies for novel biologics even when referencing overseas approvals. South Korea’s Ministry of Food and Drug Safety has moved toward greater reliance on international decisions but still requires local pharmacovigilance structures. Mainland China’s National Medical Products Administration operates a distinct dossier system with its own inspection and data localisation requirements that reliance frameworks do not simplify to the same degree as smaller jurisdictions. ImmunityBio has publicly committed to engaging additional health authorities across the Asia-Pacific region, and industry observers tracking the company’s trajectory note that the pace of that engagement will be a meaningful indicator of how seriously the company is investing in Asian commercial infrastructure versus simply building a regulatory map.

Financial position and the tension between global ambition and operational capacity

ImmunityBio’s international expansion narrative sits against a financial backdrop that warrants scrutiny from industry observers. The company has operated with a significant cash burn profile associated with its clinical development programme and commercial launch infrastructure in the United States. The scale of investment required to build distribution, medical affairs, and market access capabilities across 34 jurisdictions is not trivial, and ImmunityBio’s commercial scale relative to larger oncology players limits the resources it can deploy in parallel across markets. The Macau approval, achieved via a low-cost reliance pathway, is the kind of regulatory milestone that can be announced at modest incremental expense. Whether the pipeline of applications targeting larger Asia-Pacific markets will translate into funded, staffed commercial operations, rather than approvals on paper, is the substantive question that analysts and investors will be monitoring.

The supplemental BLA resubmission for the papillary-only NMIBC indication in the United States, if approved, would extend the addressable population meaningfully in the company’s largest market. The FDA’s Type B End-of-Phase meeting held in January 2026 indicated regulatory engagement, and the resubmission in March 2026 suggests ImmunityBio believes the chemistry, manufacturing, and controls issues that prompted the earlier complete response letter have been addressed. A positive outcome for that application would strengthen the company’s overall regulatory narrative and likely support its international dossier quality for markets where FDA precedent carries weight.

Unresolved questions that clinicians and regulators will continue to watch

Several substantive uncertainties surround ANKTIVA’s broader trajectory. The single-arm trial design of QUILT-3.032, while appropriate given the limited patient population and the ethical complexity of a placebo arm in a BCG-unresponsive setting, means that real-world registry data and post-marketing cohort studies will be important in confirming the durability signals observed in the clinical setting. BCG supply constraints, which have periodically affected urology practices in multiple markets, create a practical operational dependency for a therapy that requires the combination to deliver its effect. Regulatory agencies in markets where ANKTIVA is not yet approved may ask whether the efficacy data, predominantly derived from U.S. and North American sites, generalises across different patient populations with potentially different BCG administration histories and surveillance standards.

The competitive landscape is also evolving. Several other agents are in development for BCG-unresponsive NMIBC, including intravesical formulations and systemic immunotherapies with different mechanistic profiles. If any of these generate randomised controlled trial data against BCG alone or against ANKTIVA plus BCG as an active comparator, the evidentiary bar for the entire field will shift. For now, ANKTIVA occupies a relatively unchallenged position at the intersection of novel immunomechanism and demonstrated regulatory acceptance across multiple stringent agencies. The Macau authorisation adds a geographic data point to that story, even if it adds little near-term commercial weight.

  ANKTIVA, Asia-Pacific pharma, BCG-unresponsive NMIBC, bladder cancer, IL-15 agonist, ImmunityBio, interleukin-15, Macau regulatory approval, nogapendekin alfa inbakicept, non-muscle invasive bladder cancer, QUILT-3.032, reliance regulatory pathway